PharmaTher Holdings Ltd. has been granted a U.S. patent for using ketamine to treat Amyotrophic Lateral Sclerosis (ALS), bolstering their existing Orphan Drug Designation from the FDA. This patent protects their clinical development program and gives them a significant advantage in developing treatments for this debilitating disease. This development builds upon their current Phase 2 clinical study for ketamine in ALS.
This patent is crucial for ALS patients who currently have limited treatment options offering only minor relief from disease progression. The combination of patent protection and orphan drug status offers a promising new avenue for developing a truly effective therapy, addressing a significant unmet medical need. This could lead to a substantial improvement in patients’ quality of life and potentially extend survival.
The patent provides PharmaTher exclusive rights to this specific ketamine treatment for ALS until May 14, 2041. The FDA’s Orphan Drug Designation grants seven years of market exclusivity upon drug approval, plus tax credits, fee exemptions, and regulatory support. PharmaTher also aims to secure Fast Track designation from the FDA after completion of their current Phase 2 clinical trial. The global ALS treatment market is projected to exceed $1.04 billion by 2030, offering substantial commercial potential. Approximately 5,000 new ALS cases are diagnosed annually in the U.S., with around 30,000 Americans currently living with the disease.
This patent strengthens PharmaTher’s position as a leader in ketamine-based therapies for neurological disorders. It allows them to pursue further clinical development, attract potential partnerships, and potentially bring a transformative treatment to market. This step forward not only benefits PharmaTher but also signals a potential turning point in the fight against ALS, offering hope for more effective treatments in the future.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
